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PCN5
SOFRAFENIB VERSUS SUNITINIB IN METASTATIC RENAL CELL 
CARCINOMA: INDIRECT COMPARISON ANALYSIS
Leung HW1, Chan AL2
1Taipei Medical University- Shuang Ho Hospital, Taipei, Taiwan; 2Chi Mei Medical Center, 
Tainan, Taiwan
OBJECTIVES: To evaluate the clinical effectiveness of sorafenib and sunitinib in 
metastatic renal cell carcinoma (RCC) by using indirect comparison meta-analysis. 
METHODS: Systematic literature search of Medline, Embase, Cochrane controlled 
trials register. All randomized clinical trials of sorafenib or sunitinib versus interferon 
alfa for treating metastatic renal-cell carcinoma were included. Study selection, data 
extraction and quality assessment were performed by two reviewers with disagree-
ments being resolved by consensus. The effects of sorafenib and sunitinib on progres-
sion-free survival were compared indirectly using indirect treatment comparison 
program, with interferon alfa (IFN) as a common comparator. RESULTS: Two studies 
were included. Median progression-free survival was prolonged with the treatment of 
sunitinib (11 months) compared to interferon alfa (5 months). For the comparison of 
sorafenib and interferon-alfa, the median progression-free survival was similar 
(median PFS: 5.7 months vs. 5.6 months). Indirect comparison suggests that sunitinib 
is not superior to sorafenib for prolongation of progress free survival (hazard ratio 
0.37; 95% CI: 0.236–0.58, P = 0.0189). CONCLUSIONS: There is no signiﬁ cant 
evidence to suggest that treatment with sunitinib has clinical advantages over treat-
ment with sorafenib in patients with metastatic RCC. 
PCN6
RISK OF BREAST CANCER AMONG USERS OF POSTMENOPAUSAL 
HORMONE REPLACEMENT THERAPY IN TAIWAN
Shen WC1, Lin MS2, Bai CH3, Chen WC4, Tang CH4
1Taipei Medical University and Wan Fang Hospital, Taipei, Taiwan; 2National Taiwan 
University and National Taiwan University Hospital, Taipei, Taiwan; 3Taipei Medical 
University/Shin Kong WHS Memorial Hospital, Taipei, Taiwan; 4Taipei Medical University, 
Taipei, Taiwan
OBJECTIVES: To determine whether the association between the different dosage of 
hormone replacement therapy (HRT) and the incidence of breast cancer (BC) in 
postmenopausal women with HRT formulation. METHODS: Patients who had at least 
one outpatient visit for postmenopausal syndrome (ICD-9-CM code 627) with estrogen 
prescription in Taiwan National Health Insurance (NHI) claims database during 1999–
2006 were identiﬁ ed as the study cases. There were 883,052 women identiﬁ ed from the 
dataset. The index date was deﬁ ned as the date of the ﬁ rst menopausal visit with estrogen 
prescription during the study period. To identify any BC events, each case was tracked 
from the index date until December 31, 2006 or death, whichever came ﬁ rst. Women 
without events were censored on December 31, 2006. Survival analysis was performed 
to assess whether cumulative estrogen dosage and combined progesterone were inde-
pendent risk factors of BC. RESULTS: A total of 5524 cases of BC were identiﬁ ed during 
the study period. Women with higher dosage of estrogen had signiﬁ cantly higher risk 
of BC than women with lower dosage (HR = 2.23; P < 0.0001). The risk of BC was 
even higher when progesterone was combined with estrogen (HR = 1.08; P = 0.036). 
Women aged 60–69 (HR = 0.87, P = 0.002) and >70 (HR = 0.66, P < 0.0001) had 
lower risk of BC, compared with women aged <60. Women living in the northern part 
of Taiwan and in areas with higher urbanization level had higher risk of BC, compared 
with their counterparts. CONCLUSIONS: Hormone replacement therapy in post-
menopausal women seemed to be associated with an increased risk of BC. 
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ESTIMATION ON THE INCIDENCE OF SELECTED CANCERS IN CHINA, 
2004
Li R1, Hu SY2, Lin M3, Wang D4, Dong P4
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OBJECTIVES: This study is to investigate the characteristics on incidence of stomach, 
lung, liver, breast and kidney cancer, and to estimate the total number of new cancer 
cases in China in 2004. METHODS: Incidence data were collected through 37 local 
cancer registries across 19 provinces and autonomous regions in China, 2004. Data 
were classiﬁ ed by ICD-10 and processed according to international cancer registration 
guidelines. The number of new cancer cases was estimated by local cancer registry 
data, residence population in the corresponding areas, and the population of China 
in 2004. RESULTS: Registry data covered a population of 57,698,672 residents, 
accounting for 4.44% of Chinese population in 2004. There were 73,552 new cancer 
cases registered, with world age-adjusted incidence by cancer type ranging from 2.69 
per 100,000 to 31.55 per 100,000. Overall, lung cancer was highest in incidence rate, 
followed by cancer of stomach, liver and breast, while kidney cancer accounted for a 
relatively small proportion. Cancer among urban residents by incidence per 100,000 
was lung (33.19), stomach (18.22), breast (16.52), liver (15.83) and kidney (3.32), 
while in rural residents was stomach (40.35), liver (28.66), lung (26.30), breast (6.19), 
and kidney (0.68). Cancer in men by incidence per 100,000 was lung (44.21), stomach 
(33.32), liver (28.94) and kidney (3.50), while in women was breast (27.76), lung 
(19.98), stomach (14.06), liver (8.97) and kidney (1.94). Total cancer incidence was 
estimated 30,571,904 in china in 2004. Estimation of cancer incidence of stomach, 
lung, liver, breast and kidney was 10,609,682, 7,335,176, 5,927,478, 2,492,148, and 
376,927, respectively. CONCLUSIONS: Cancer incidence rates vary by region and 
gender in China. The overall burden of cancer is heavy and more attention should be 
paid to cancer prevention and control. 
CANCER – Cost Studies
PCN8
IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA 
PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A 
COMMERCIALLY INSURED POPULATION IN THE UNITED STATES
Tsong W1, Singer ME2, Ray S1
1Abbott Laboratories, Abbott Park, IL, USA; 2Case Western Reserve University School of 
Medicine, Cleveland, OH, USA
OBJECTIVES: Although hepatocellular carcinoma (HCC) is a highly prevalent disease 
in East Asia with a growing incidence in the US, there is a limited understanding of 
health-care procedures and their economic impact. This study identiﬁ es the procedures 
with the highest payer budget impact in a commercially insured US population. 
METHODS: The MEDSTAT insurance claims database (January 1, 2000–December 
31, 2008) was used to identify a cohort of patients with > = 1 HCC claim (index = 
ﬁ rst claim), age > = 18, and no other cancer diagnoses. For each procedure code, all 
payments (2009 USD) were summed across the cohort and divided by the total patient-
months to estimate the per patient-month (PM) cost. The PM costs were ranked to 
identify procedures with the highest payer budget impact. The proportion of patients 
utilizing each procedure was calculated to evaluate whether PM costs were driven by 
a minority of patients. RESULTS: The study sample included 2927 patients: mean age 
50.4 years, 57% male, and median 9 months follow-up. The inpatient procedures with 
the highest budget impact were: liver transplant and/or intestinal transplant ($526/
PM, 4.6% of patients), tracheostomy with mechanical ventilation ($204/PM, 0.2%), 
disorders of liver except malignancy/cirrhosis/alcoholic hepatitis ($96/PM, 5.1%). For 
hospital outpatient procedures, they were: magnetic resonance imaging (MRI) of the 
abdomen ($18/PM, 15%), computed tomography of abdomen ($13/PM, 17%), and 
transcatheter occlusion/embolization ($8/PM, 4%). For ofﬁ ce outpatient procedures, 
they were: low complexity visits ($26/PM, 70%), moderate complexity visits ($18/
PM, 18%), and MRI of abdomen ($8/PM, 7%). Patients with > = 1 sorafenib prescrip-
tion (<2% of cohort) had a minimal impact on the results. CONCLUSIONS: The key 
procedures with the highest budget impact appear to be related to both cancer and 
liver disease. These costs may be reduced with improved anticancer therapy which 
provides better cancer control and reduces the exacerbation of liver disease from 
tumor growth. 
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FIRST YEAR MEDICAL CARE COSTS ASSOCIATED WITH 
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OBJECTIVES: Although hepatocellular carcinoma (HCC) is highly prevalent in East 
Asia with a growing incidence in the United States, the economic impact of the disease 
has not been extensively studied. This study compares medical costs of HCC patients 
in the ﬁ rst year after diagnosis with those of non-cancer controls. METHODS: A 
Medicaid database (July 1, 2001–June 30, 2007) was used to identify cases with > = 
1 HCC claim, > = 1 HCC post-index claim, and no other cancers. Controls were 
matched on age, sex, and race. Costs (2008 USD) for medical care services (inpatient, 
outpatient, emergency room [ER], long-term care [home health, nursing home, 
hospice]) were analyzed as ﬁ rst-year costs and follow-up adjusted costs (per-patient-
per-month [PPPM]). All costs were compared using rank sum tests. RESULTS: The 
study identiﬁ ed 126 HCC cases and 126 controls: mean age 49 years, 51% male, 
mean follow-up months: 9.2 cases/11.9 controls, and deaths: 29.4% cases/1.6% 
controls. First-year costs were 1.5 to 8 times higher in cases versus controls (long-term 
care $3752 vs. $2554, ER $126 vs. $51, outpatient $4143 vs. $1412, inpatient 
$12,425 vs. $1595, all with P < 0.012). PPPM costs were 3 to 27 times higher in cases 
versus controls (long-term care $626 vs. $233, outpatient $884 vs. $119, ER $34 vs. 
$4, inpatient $3738 vs. $139, all with P < 0.001). Total costs were two times higher 
for HCC cases in the ﬁ rst year ($29,795 vs. $13,151, P < 0.001) and six times higher 
as PPPM ($6376 vs. $1125, P < 0.001). No patients had a sorafenib prescription. 
CONCLUSIONS: First-year medical care costs were substantially higher for the HCC 
patients, and even higher when adjusted for follow-up on a PPPM basis. Future thera-
pies that improve survival and disease control may enable payers to reduce monthly 
costs, and use the savings to treat other patients. 
PCN10
ESTIMATION OF THE HEALTH AND COST BURDEN OF HPV-RELATED 
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BACKGROUND: Cervical cancer is the ﬁ rst leading female cancer, especially, in 
developing countries. The two available HPV vaccines protect against HPV types 
16/18 responsible for majority of cervical cancer. The quadrivalent vaccine also 
protects against HPV types 6/11 that cause majority of genital warts. It is important 
